Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy

Zonghui Ma, Yu Ji, Yifan Yu, Dailin Liang

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

As a newly emerged technology, PROTAC (proteolysis targeting chimera) is a promising therapeutic strategy for varieties of diseases. Unlike small molecule inhibitors, PROTACs catalytically induce target proteins degradation, including currently “undruggable” target proteins. In addition, PROTACs can be a potentially successful strategy to overcome drug resistance. IAPs can inhibit apoptosis by inhibiting caspase, and also exhibits the activity of E3 ubiquitin ligase. Specific and nongenetic IAP-based protein erasers (SNIPERs) are hybrid molecules that designed based on IAPs, and used to degrade the target proteins closely associated with diseases. Their structures consist of three parts, including target protein ligand, E3 ligase ligand and the linker between them. SNIPERs (PROTACs) degrade diseases-associated proteins through human inherent ubiquitin-proteasome system. So far, many SNIPERs have been developed to treat diseases that difficult to handle by traditional methods, such as radiotherapy, chemotherapy and small molecule inhibitors, and showed promising prospects in application. In this paper, the recent advances of SNIPERs were summarized, and the chances and challenges associated with this area were also highlighted.

Original languageEnglish (US)
Article number113247
JournalEuropean journal of medicinal chemistry
Volume216
DOIs
StatePublished - Apr 15 2021
Externally publishedYes

Keywords

  • Antitumor
  • IAPs
  • PROTAC
  • Protein degradation
  • SNIPER
  • Ubiquitin-proteasome system (UPS)

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy'. Together they form a unique fingerprint.

Cite this